Date: 2012-01-12
Type of information: Fundraising
Company: ProteoMediX (Switzerland)
Investors: Altos Venture (Switzerland) - BioValley Business Angels Club BioBAC (Switzerland) - Zürcher Kantonalbank (Switzerland)
Amount: CHF 2.6 million (€2.1 million)
Funding type: Series A equity financing round
Planned used: The new funds will enable ProteoMediX to continue the development of diagnostic tests in the field of prostate cancer and to expand its operations. The company\'s proprietary protein-based biomarkers showed a significantly increased accuracy in detecting prostate cancer when compared to the current standard PSA test. The innovative proteomics technology that was applied to find these biomarkers enables the development of non-invasive diagnostics directly linked to the origin of cancer on a molecular level. This allows ProteoMediX to address additional diagnostic applications such as assessing the prognosis of the disease as well as to match prostate cancer patients with safer and more effective therapies.
Others: ProteoMediX AG, a diagnostic company developing non- invasive diagnostic tests for the accurate detection, prognosis and therapy-selection of cancer, has announced the successful closing of a Series A equity financing round. The board of directors will be strengthened with Dr. Werner Schaefer and Dr. Isaac Kobrin. Dr. Schaefer. He was a member of the management board at Roche Diagnostics and before that held a leading management position at Abbott Diagnostics. Dr. Kobrin was responsible for the worldwide clinical development of key compounds at Roche and subsequently joined Actelion as head of clinical development and later was appointed to Chief Medical Officer
Therapeutic area: Cancer - Oncology
